Quarterly report · Q1
2160.TEDINET S100TFYV
Period2024-01-01 → 2024-03-31
Filed2024-05-15
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.9bn | 2024-01-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥26.0bn | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥4.2bn | 2023-01-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Operating income | ¥2.3bn | 2024-01-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥398m | 2023-01-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥1.8bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥12.6bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥65m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥1.5bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥8.1bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥3m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥1.3bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥9.5bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥342m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥65.6bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥62.4bn | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥34.1bn | at 2023-03-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥27.8bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥26.3bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥37.8bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥36.1bn | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.8bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.8bn | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥34.6bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥33.8bn | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥21.2bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥20.3bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥21.6bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥10.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.0bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥350m | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥6.5bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥710m | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥1.8bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥6.8bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥1.2bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥88m | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥10.7bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥52m | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥29.17 | 2024-01-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥169.5 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-0.06 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥28 | 2024-01-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥165.56 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-0.06 | 2023-01-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 52.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 54.2% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.2% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 22
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥1.3bn |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥1.3bn |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥539m |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥4.6bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥4.6bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥1.7bn |
| —segment total | revenue | 2024-01-01 → 2024-03-31 | ¥5.9bn |
| —segment total | revenue external | 2024-01-01 → 2024-03-31 | ¥5.9bn |
| —segment total | segment profit | 2024-01-01 → 2024-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-03-31 | −¥23m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-03-31 | −¥23m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥623m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥600m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥23m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥248m |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥3.6bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥3.6bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥149m |
| —segment total | revenue | 2023-01-01 → 2023-03-31 | ¥4.2bn |
| —segment total | revenue external | 2023-01-01 → 2023-03-31 | ¥4.2bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥23m |
| —segment total | segment profit | 2023-01-01 → 2023-03-31 | ¥398m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 599
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenue IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenue IFRS | CurrentYTDDuration | 5948569000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E05712-000PharmaceuticalReportableSegmentMember | 1744687000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_jpcrp040300-q1r_E05712-000MedicalDeviceReportableSegmentMember | 539131000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReportableSegmentsMember | 2283819000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Operating profit loss IFRS | CurrentYTDDuration | 2283819000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 161678000 | JPY |
| Finance costs IFRS | CurrentYTDDuration | 629737000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration | 11412000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 1827172000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-05-15 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第24期第１四半期（自 2024年１月１日 至 2024年３月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社ジーエヌアイグループ | |
| Company name in english cover page | FilingDateInstant | GNI Group Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)取締役代表執行役社長兼CEO イン・ルオ | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋本町二丁目２番２号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)03（6214）3600（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役執行役CFO 北川 智哉 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋本町二丁目２番２号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)03（6214）3600（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役執行役CFO 北川 智哉 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05712 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 21600 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社ジーエヌアイグループ | |
| Filer name in english | FilingDateInstant | GNI Group Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-01-01 | |
| Current period end date | FilingDateInstant | 2024-03-31 | |
| Type of current period | FilingDateInstant | Q1 | |
| Current fiscal year end date | FilingDateInstant | 2024-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-01-01 | |
| Comparative period end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2023-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |